Literature DB >> 6958392

Metabolism of daunorubicin in sensitive and resistant Ehrlich ascites tumor cells. Determination by high pressure liquid chromatography.

D Londos-Gagliardi, R Baurain, J Robert, G Aubel-Sadron.   

Abstract

The intracellular metabolism of daunorubicin (DNR) has been studied in sensitive and resistant Ehrlich ascites tumor (EAT) cells. The subcellular localization of metabolites has been followed by normal-phase and reverse-phase high-pressure liquid chromatography (HPLC). The metabolism of DNR by either sensitive or resistant EAT cells is not significant; unmetabolized DNR is always the main intracellular compound. Daunorubicinol (DOL) accounts for less than 5% after 24 h and an unidentified product is also observed. This highly apolar compound, having an intrinsic fluorescence one order of magnitude greater than that of DNR is formed in acellular conditions and could be a chemical artifact. DNR and DOL are mainly associated with DNA-containing fractions. No significant differences can be observed in the metabolism of DNR in sensitive and resistant EAT cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6958392     DOI: 10.1007/bf00296761

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  19 in total

1.  Binding of daunomycin to DNA and the inhibition of RNA and DNA synthesis.

Authors:  N S Mizuno; B Zakis; R W Decker
Journal:  Cancer Res       Date:  1975-06       Impact factor: 12.701

2.  Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue.

Authors:  C DE DUVE; B C PRESSMAN; R GIANETTO; R WATTIAUX; F APPELMANS
Journal:  Biochem J       Date:  1955-08       Impact factor: 3.857

3.  Heterogeneity of anthracycline antibiotic carbonyl reductases in mammalian livers.

Authors:  N K Ahmed; R L Felsted; N R Bachur
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

4.  Microsomal reductive glycosidase.

Authors:  N R Bachur; M Gee
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

5.  Interaction between daunorubicin and chromatin from Ehrlich ascites tumor cells.

Authors:  G Sabeur; D Genest; G Aubel-Sadron
Journal:  Biochem Biophys Res Commun       Date:  1979-05-28       Impact factor: 3.575

6.  The inhibition of RNA polymerase by daunomycin.

Authors:  F Zunino; A Di Marco; A Zaccara; G Luoni
Journal:  Chem Biol Interact       Date:  1974-07       Impact factor: 5.192

7.  Daunorubicin reductase activity in leukemia leukocyte homogenates.

Authors:  A Gola
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1979       Impact factor: 4.291

8.  Daunorubicin metabolism in acute myelocytic leukemia.

Authors:  D H Huffman; N R Bachur
Journal:  Blood       Date:  1972-05       Impact factor: 22.113

9.  Uptake and subcellular localization of daunorubicin and adriamycin in cultured fibroblasts.

Authors:  G Noel; C Peterson; A Trouet; P Tulkens
Journal:  Eur J Cancer       Date:  1978-04       Impact factor: 9.162

10.  Subcellular localization of daunorubicin in sensitive and resistant Ehrlich ascites tumor cells.

Authors:  D Londos-Gagliardi; G Aubel-Sadron; R Maral; A Trouet
Journal:  Eur J Cancer       Date:  1980-06       Impact factor: 9.162

View more
  2 in total

1.  Positive correlation between decreased cellular uptake, NADPH-glutathione reductase activity and adriamycin resistance in Ehrlich ascites tumor lines.

Authors:  M E Scheulen; H Hoensch; H Kappus; S Seeber; C G Schmidt
Journal:  Arch Toxicol       Date:  1987       Impact factor: 5.153

Review 2.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.